Raymond James Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained an 'Outperform' rating on Intellia Therapeutics (NASDAQ:NTLA), but lowered the price target from $78 to $57.
November 10, 2023 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics' price target has been lowered from $78 to $57 by Raymond James, although the 'Outperform' rating is maintained.
The lowering of the price target by Raymond James could lead to a short-term negative impact on Intellia Therapeutics' stock price. However, the maintained 'Outperform' rating indicates that the analyst still sees potential in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100